Immutep raises $68m to fund cancer trials until 2026
SYDNEY: Immutep, an immunotherapy-focused biotech, has raised $68m from institutional investors to fund ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
